Sunshine Biopharma (SBFM) Stock
Small biotech company developing drug candidates for market approval. Here's the price, business snapshot, and what's worth knowing about Sunshine Biopharma in October 2026.
Sunshine Biopharma Inc (ticker: SBFM) is a micro‑capitalisation biotechnology company. With a market capitalisation around $8.75m, it is likely a small, development‑stage firm where investor outcomes hinge on drug‑development progress, regulatory decisions, partnerships and access to capital. Shares can be thinly traded and prone to sharp swings on trial readouts, licensing news or fundraising announcements. Common risks include limited cash runway, the binary nature of clinical results, regulatory uncertainty and potential dilution from new equity issues. Potential upside exists if programmes advance or strategic deals are struck, but such outcomes are uncertain and not guaranteed. This summary is for general, educational purposes only and is not personalised investment advice; investors should review company filings, consider their risk tolerance and seek independent financial advice as appropriate.
Sunshine Biopharma (SBFM) Stock Forecast
Analyst price target, next 12 months
$178.00
+114295.9% vs today's $0.16
Price range over the last 12 months
Close to its 12-month low
Analysts covering Sunshine Biopharma have a consensus 12-month target of $178.00, above the current price of $0.16.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 24 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Sunshine Biopharma stock with a target price of $178, indicating significant growth potential.
Financial Health
Sunshine Biopharma is showing strong revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Binary Clinical Catalysts
Trial readouts and regulatory milestones can drive large price moves; outcomes can be binary and uncertain, so performance may vary.
Financing & Dilution
Small biotechs often require additional capital. Monitor cash runway and fundraising terms, as new financing can dilute existing holders.
Partnership Potential
Collaborations or licensing deals with larger firms can materially change prospects, though they depend on positive data and successful negotiations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
